बांग्लादेश - अंग्रेज़ी - DGDA (Directorate General of Drug Administration)

doctor tims pharmaceuticals ltd. - nicotinamide + pyridoxine hydrochloride + riboflavin + vitamin b1 - syrup - 20 mg + 2 mg + 2 mg + 5 mg/5 ml

बांग्लादेश - अंग्रेज़ी - DGDA (Directorate General of Drug Administration)

united chemicals & pharmaceuticals ltd. - nicotinamide + pyridoxine hydrochloride + riboflavin + vitamin b1 - syrup - 20 mg + 2 mg + 2 mg + 5 mg/5 ml

युगांडा - अंग्रेज़ी - National Drug Authority

gittoes pharmaceuticals limited; gittoes pharmaceuticals limited - vitamin b1 + vitamin b2 + nicotinamide + vitamin b6 - oral solid ordinary coated tablets - 1.0 mg + 1.0 mg + 15 mg + 0.5 mg

केन्या - अंग्रेज़ी - Pharmacy and Poisons Board

brimonidine tartrate and timolol eye drops - eye drops - brimonidine tartrae-2 mg and timolol maleate eq… - timolol combinations

सिंगापुर - अंग्रेज़ी - HSA (Health Sciences Authority)

biomed diagnostics pte ltd - hematology - a high sensitivity thromboplastin reagent based on recombinant human tissue factor (rtf) for the quantitative determination in human citrated plasma of prothrombin time (pt) and fibrinogen on il coagulation systems. the product is used for the evaluation of the extrinsic coagulation pathway and the monitoring of oral anticoagulant therapy (oat).

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ramipril, quantity: 10 mg - tablet, uncoated - excipient ingredients: sodium stearylfumarate; pregelatinised maize starch; sodium bicarbonate; microcrystalline cellulose; hypromellose - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. post mi heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or an antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ramipril, quantity: 5 mg - tablet, uncoated - excipient ingredients: sodium bicarbonate; microcrystalline cellulose; sodium stearylfumarate; hypromellose; pregelatinised maize starch - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. post mi heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ramipril, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; sodium stearylfumarate; microcrystalline cellulose; hypromellose; sodium bicarbonate - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. post mi heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ramipril, quantity: 1.25 mg - tablet, uncoated - excipient ingredients: sodium bicarbonate; pregelatinised maize starch; hypromellose; microcrystalline cellulose; sodium stearylfumarate - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. post mi heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - glibenclamide, quantity: 5 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; pregelatinised maize starch; lactose monohydrate; purified talc; maize starch - daonil and semi-daonil are indicated as an adjunct to diet to lower the blood glucose in patients with non-insulin-dependent diabetes mellitus (type 2) whose hyperglycaemia cannot be controlled by diet alone. because of its broad and predictable action, daonil and semi-daonil are often suitable for the management of patients who have failed to respond to other oral antidiabetics.,in initiating treatment for non-insulin-dependent diabetes, diet should be emphasised as the primary form of treatment. caloric restriction and weight loss are essential in the obese diabetic patient. proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycaemia. the importance of regular physical activity should also be stressed, and cardiovascular risk factors should be identified and corrective measures taken where possible. if this treatment programme fails to reduce symptoms and/or blood glucose the use of an oral sulphonylurea should be considered. use of daonil and semi-daonil must be viewed by both the physician and patient as a treatment in addition to diet, and not as a substitute for diet or as a convenient mechanism for avoiding dietary restraint.